Association of the interleukin-10 -592A/C, -1082G/A and -819T/C gene polymorphisms with type 2 diabetes: A meta-analysis

Gene

Volumn 521, Issue 2, 2013, Pages 211-216

  Li, Jing ^a   Wu, Song ^a   Wang, Ming Rui ^a   Wang, Ting Ting ^a   Zhu, Ji Min ^a  

^a ANHUI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Genetic polymorphisms; Interleukin 10; Meta analysis; Type 2 diabetes

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; CONSENSUS; CYTOKINE RELEASE; ETHNICITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW;

ALLELES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-10; POLYMORPHISM, GENETIC;

EID: 84876991028     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.03.072     Document Type: Review

References (37)

1. Arababadi M.K., et al. Interleukin (IL)-10 gene polymorphisms are associated with type 2 diabetes with and without nephropathy: a study of patients from the southeast region of Iran. Inflammation 2012, 35:797-802.
2. Asderakis A., et al. Association of polymorphisms in human interferon-gamma and interleukin-10 gene with acute and chronic kidney transplant outcome: the cytokine effect on transplantation. Transplantation 2001, 15:674-677.
3. Chang Y.H., Huang C.N., Wu C.Y., Shiau M.Y. Association of interleukin-10 A-592C and T-819C polymorphisms with type 2 diabetes mellitus. Hum. Immunol. 2005, 66:1258-1263.
4. Cochran W.G. The combination of estimates from different experiments. Biometrics 1954, 10:101-129.
5. D'Andrea A., Aste-Amezaga M., Valiante N.M., Ma X., Kubin M., Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 1993, 178:1041-1048.
6. de Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., de Vries J.E. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 1991, 174:1209-1220.
7. Del Prete G., De Carli M., Almerigogna F., Giudizi M.G., Biagiotti R., Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J. Immunol. 1993, 150:353-360.
8. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
9. Edwards-Smith C.J., Jonsson J.R., Purdie D.M., Bansal A., Shorthouse C., Powell E.E. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999, 30:526-530.
10. Erdogan M., Cetinkalp S., Ozgen A.G., Saygili F., Berdeli A., Yilmaz C. Interleukin-10 (-1082G/A) gene polymorphism in patients with type 2 diabetes with and without nephropathy. Genet. Test. Mol. Biomarkers 2012, 16:91-94.
11. Eskdale J., Kube D., Tesch H., Gallagher G. Mapping of the human IL10 gene and further characterization of the 5' flanking sequence. Immunogenetics 1997, 46:120-128.
12. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 1991, 147:3815-3822.
13. Florez J.C. Clinical review: the genetics of type 2 diabetes: a realistic appraisal in 2008. J. Clin. Endocrinol. Metab. 2008, 93:4633-4642.
14. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21:1539-1558.
15. Howell W.M., Rose-Zerilli M.J. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J. Nutr. 2007, 137:194S-199S.
16. Jin W., Patti M.E. Genetic determinants and molecular pathways in the pathogenesis of Type 2 diabetes. Clin. Sci. (Lond.) 2009, 116:99-111.
17. Joshi S.K., Shrestha S. Diabetes mellitus: a review of its associations with different environmental factors. Kathmandu Univ. Med. J. (KUMJ) 2010, 8:109-115.
18. Kube D., et al. Isolation of human IL10 promoter. Characterization of promoter activity in Burkitt's lymphoma cell lines. Cytokine 1995, 7:1-7.
19. Kung W.J., Lin C.C., Liu S.H., Chaung H.C. Association of interleukin-10 polymorphisms with cytokines in type 2 diabetic nephropathy. Diabetes Technol. Ther. 2010, 12:809-813.
20. Lin Y., Sun Z. Current views on type 2 diabetes. J. Endocrinol. 2010, 204:1-11.
21. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22:719-748.
22. Mtiraoui N., et al. Predictive value of interleukin-10 promoter genotypes and haplotypes in determining the susceptibility to nephropathy in type 2 diabetes patients. Diabetes Metab. Res. Rev. 2009, 25:57-63.
23. Munafò M.R., Flint J. Meta-analysis of genetic association studies. Trends Genet. 2004, 20:439-444.
24. Nakaoka H., Inoue I. Meta-analysis of genetic association studies: methodologies, between-study heterogeneity and winner's curse. J. Hum. Genet. 2009, 54:615-623.
25. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27:813-823.
26. Qi L., Hu F.B., Hu G. Genes, environment, and interactions in prevention of type 2 diabetes: a focus on physical activity and lifestyle changes. Curr. Mol. Med. 2008, 8:519-532.
27. Rees L.E., Wood N.A., Gillespie K.M., Lai K.N., Gaston K., Mathieson P.W. The interleukin-10 -1082G/A polymorphism: allele frequency in different populations and functional significance. Cell. Mol. Life Sci. 2002, 59:560-569.
28. Rosenwasser L.J., Borish L. The rational behind promoter-based candidate gene studies (IL-4 and IL-10). Am. J. Respir. Crit. Care Med. 1997, 156:S152-S155.
29. Saxena M., Agrawal C.G., Bid H.K., Banerjee M. An interleukin-10 gene promoter polymorphism (-592A/C) associated with type 2 diabetes: a North Indian Study. Biochem. Genet. 2012, 50:549-559.
30. Scarpelli D., et al. Variants of the interleukin-10 promoter gene are associated with obesity and insulin resistance but not type 2 diabetes in caucasian italian subjects. Diabetes 2006, 55:1529-1533.
31. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010, 87:4-14.
32. Stanilova S.A., Miteva L.D., Karakolev Z.T., Stefanov C.S. Interleukin-10 -1082 promoter polymorphism in association with cytokine production and sepsis susceptibility. Intensive Care Med. 2006, 32:260-266.
33. Tsiavou A., et al. TNF-alpha, TGF-beta1, IL-10, IL-6, gene polymorphisms in latent autoimmune diabetes of adults (LADA) and type 2 diabetes mellitus. J. Clin. Immunol. 2004, 24:591-599.
34. Turner D.M., Williams D.M., Sankaran D., Lazarus M., Sinnott P.J., Hutchinson I.V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur. J. Immunogenet. 1997, 24:1-8.
35. van Exel E., Gussekloo J., de Craen A.J.M., Frölich M., Bootsma-van der Wiel A., Westendorp R.G.J. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 2002, 51:1088-1092.
36. Wang J.D., Fang H., Yan Q.Z., Zhou D.H., Yao H.J. Relationship of serum interleukin-10 level and its gene promoter 592 polymorphism to type 2 diabetes mellitus. Chin. Gen. Pract. 2010, 13:1185-1188. (in Chinese).
37. Westendorp R.G., et al. Genetic influence on cytokine production and fatal eningococcal disease. Lancet 1997, 349:170-173.